Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06878404 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
A Phase 3 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 552
- Enrollment target
- 20
- Study locations
NCT06878404: Active Phase 3 study of Arthritis, Psoriatic, sponsored by Janssen Research & Development.
NCT06878404 is a Phase 3 study of Arthritis, Psoriatic that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 552 participants, roughly in line with the 542-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06878404, a Phase 3 study of Arthritis, Psoriatic, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 552 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Primary Outcome
The ACR 20 responders are participants with an improvement of greater than or equal to (\>=) 20 percent (%) from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain visual analog scale (VAS), patient's global assessment of disease activity VAS scale, physician's global assessment of disease activity VAS scale, health assessment questionnaire and C-reactive protein).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Icotrokinra
- DRUG Active reference comparator
Study Locations (20)
Other
- Cosultorios Reumatologógicos Pampa - Buenos Aires
- Mindout Research - Buenos Aires
- Hospital Central Militar Cirujano Mayor Dr Cosme Argerich - Buenos Aires
- Arsema - Ciudad de Buenos Aires
- Centro Medico Privado de Reumatologia Tucuman - Ciudad de San Miguel de Tucuman
- Consultora Integral de Salud SRL - Córdoba
- MR Medicina Reumatologica - San Fernando
- Instituto Medico De Alta Complejidad (IMAC) - San Isidro
- Ipswich Hospital - Ipswich
- Rheumatology Research Unit - Maroochydore
- BJC Health - Parramatta
Florida
- Omega Research Consultants - DeBary
- Integral Rheumatology And Immunology Specialists - Plantation
- Clinical Research of West Florida - Tampa
Texas
- Arthritis and Rheumatology Research Institute - Allen
- Naiara Alvarez MD Integrative Rheumatology of South TX - Harlingen
Arkansas
- Arthritis and Rheumatism Associates ARA Jonesboro - Jonesboro
Illinois
- Willow Rheumatology and Wellness PLLC - Willowbrook
North Carolina
- Joint and Muscle Research Institute - Charlotte
Pennsylvania
- Altoona Center For Clinical Research - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 552 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2028-11-21 |
| Phase | Phase 3 |
What the registry record for NCT06878404 still lists
NCT06878404 is an interventional study that assigns participants to a tested intervention. The registered 552 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 542-participant average among 16 other Arthritis, Psoriatic trials with a reported enrollment target.
The record links to 1 condition, with Arthritis, Psoriatic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06878404 names 20 study sites across 7 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06878404 about?
NCT06878404 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis". The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
What is the current status of trial NCT06878404?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 552 participants. The study started on 2025-02-21. Estimated completion is 2028-11-21.
What conditions does trial NCT06878404 study?
This clinical trial studies the following conditions: Arthritis, Psoriatic.
What interventions are being tested in trial NCT06878404?
The interventions under investigation include: Placebo (DRUG), Icotrokinra (DRUG), Active reference comparator (DRUG).
Who is sponsoring clinical trial NCT06878404?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06878404 being conducted?
This trial has 20 study locations across Arkansas, Florida, Illinois, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Psoriatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06878404's enrollment target sits among peer trials
552 7th of 16 higher than 10 of 16 other Arthritis, Psoriatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Psoriatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RECRUITING · Phase 3
-
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RECRUITING · Phase 3
-
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RECRUITING · Phase 3
-
A Long-term Extension Study of Ustekinumab in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06217809 · 552 participants · NA
EmpowHer is Prevention Curriculum for Youth Ages 10-15 Years.
- NCT07146022 · 552 participants · Phase 3
Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)
- NCT05786924 · 554 participants · Phase 1
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI